First-line immunochemotherapy for extranodal natural killer/T cell lymphoma

We congratulate Xiao-Peng Tian and colleagues1 for their Article in The Lancet Haematology, on the achievement of the promising result of their trial investigating first-line immunochemotherapy for advanced-stage extranodal NK/T-cell lymphoma (ENKTL). With the advantage of asparaginase-based regimens and standardised radiotherapy, the outcome of ENKTL has been substantially improved during the past decade,2 particularly in early-stage disease (5-year overall survival 55–90%).3 However, the prognosis of patients with advanced-stage disease is still extremely poor with 5-year overall survival of 30–40% presenting the best effectiveness for current cytotoxic regimens.